Matthias Bodenstedt, Chief Financial Officer at MoonLake Immunotherapeutics (MLTX), sold 87,795 shares at $18.94 ($1.7M) on 2026-04-09, disclosed to the SEC on 2026-04-10.
Scheduled sale ($1.7M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.94 | 85,870 | $1.6M | 97.7% |
| 2 | $19.51 | 1,925 | $38K | 2.3% |
| Total | $18.95 avg | 87,795 | $1.7M | 100% |
| Filing → |
| MLTX | SELL | 2026-05-13 | $273K | — | Filing → |
| MLTX | SELL | 2026-04-16 | $47K | — | Filing → |
| MLTX | BUY | 2025-10-09 | $198K | — | Filing → |